Shubham Pant
The University of Texas MD Anderson Cancer Center(US)
Publications by Year
Research Areas
Pancreatic and Hepatic Oncology Research, Cancer Genomics and Diagnostics, Cancer Immunotherapy and Biomarkers, Cholangiocarcinoma and Gallbladder Cancer Studies, Colorectal Cancer Treatments and Studies
Most-Cited Works
- → Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial(2015)1,174 cited
- → NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial(2023)396 cited
- → Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials(2023)348 cited
- → Treatment sequencing in metastatic colorectal cancer(2019)327 cited
- → Metastatic Pancreatic Cancer: ASCO Guideline Update(2020)277 cited
- → First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors(2021)256 cited
- → Adagrasib in Advanced Solid Tumors Harboring aKRASG12CMutation(2023)250 cited
- → PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients(2018)244 cited
- → Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study(2023)218 cited
- → Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors(2016)213 cited